Literature DB >> 16495544

Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis.

Antonia Isabel Castillo-Rodal1, Mauricio Castañón-Arreola, Rogelio Hernández-Pando, Juan José Calva, Eduardo Sada-Díaz, Yolanda López-Vidal.   

Abstract

Mycobacterium bovis BCG is the only available vaccine against tuberculosis. Reasons for why diverse BCG substrains induce different levels of protection in clinical trials remain unclear. The aim of this study was to compare the effectiveness of 10 BCG substrains in a mouse model of pulmonary tuberculosis. BALB/c mice were subcutaneously vaccinated and 2 months later were challenged with Mycobacterium tuberculosis H37Rv by intratracheal injection. Two and 4 months after challenge, delayed-type hypersensitivity (DTH) response, lung tissue affected by pneumonia, CFU, T-cell counts, and cytokine expression (interleukin-2 [IL-2], IL-4, IL-10, and gamma interferon) were determined. A differential protective effect of the diverse BCG substrains was found. BCG Phipps led to the largest and most persistent reduction of CFU counts and of the area of pneumonia at 2 and 4 months after challenge. This protection was accompanied by reduced IL-10-producing T cells. Contemporary BCG substrains induce a wide range of protection in this animal model. These data can help in the selection of the best vaccine for human immunization and for the development of novel recombinant BCG-based vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495544      PMCID: PMC1418655          DOI: 10.1128/IAI.74.3.1718-1724.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  Immunology of tuberculosis.

Authors:  J L Flynn; J Chan
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice.

Authors:  M Lagranderie; P Chavarot; A M Balazuc; G Marchal
Journal:  Vaccine       Date:  2000-01-18       Impact factor: 3.641

Review 3.  Optimal models to evaluate the protective efficacy of tuberculosis vaccines.

Authors:  J F Griffin; D N Chinn; C R Rodgers; C G Mackintosh
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

4.  Differential transcription of the MPB70 genes in two major groups of Mycobacterium bovis BCG substrains.

Authors:  T Matsuo; S Matsumoto; N Ohara; H Kitaura; A Mizuno; T Yamada
Journal:  Microbiology       Date:  1995-07       Impact factor: 2.777

Review 5.  Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.

Authors:  K M De Cock; R E Chaisson
Journal:  Int J Tuberc Lung Dis       Date:  1999-06       Impact factor: 2.373

6.  Vaccinated mice remain more susceptible to Mycobacterium tuberculosis infection initiated via the respiratory route than via the intravenous route.

Authors:  R J North; R LaCourse; L Ryan
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

7.  Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature.

Authors:  T F Brewer
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

8.  Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG.

Authors:  M Lagranderie; A-M Balazuc; M Abolhassani; P Chavarot; M-A Nahori; F Thouron; G Milon; G Marchal
Journal:  Scand J Immunol       Date:  2002-03       Impact factor: 3.487

Review 9.  Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree.

Authors:  T Oettinger; M Jørgensen; A Ladefoged; K Hasløv; P Andersen
Journal:  Tuber Lung Dis       Date:  1999

Review 10.  BCG: the challenge continues.

Authors:  P E Fine
Journal:  Scand J Infect Dis       Date:  2001
View more
  32 in total

1.  Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis.

Authors:  Rogelio Hernandez Pando; Leon Diana Aguilar; Issar Smith; Riccardo Manganelli
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

Review 2.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

3.  Dose-dependent immune response to Mycobacterium bovis BCG vaccination in neonates.

Authors:  Virginia Davids; Willem Hanekom; Sebastian J Gelderbloem; Anthony Hawkridge; Gregory Hussey; Ronel Sheperd; Lesley Workman; Jorge Soler; Rose Ann Murray; Stanley R Ress; Gilla Kaplan
Journal:  Clin Vaccine Immunol       Date:  2006-12-20

4.  Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.

Authors:  D Aguilar; E Infante; C Martin; E Gormley; B Gicquel; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

5.  Identification of surrogates and correlates of protection in protective immunity against Mycobacterium bovis infection induced in neonatal calves by vaccination with M. bovis BCG Pasteur and M. bovis BCG Danish.

Authors:  J C Hope; M L Thom; M McAulay; E Mead; H M Vordermeier; D Clifford; R G Hewinson; B Villarreal-Ramos
Journal:  Clin Vaccine Immunol       Date:  2011-01-12

6.  A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.

Authors:  Chun Wang; Zhenhua Chen; Ruiling Fu; Ying Zhang; Lingxia Chen; Li Huang; Jinjin Li; Chunwei Shi; Xionglin Fan
Journal:  Med Microbiol Immunol       Date:  2011-02-22       Impact factor: 3.402

7.  Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals.

Authors:  Malathesha Ganachari; Jorge A Ruiz-Morales; Juan C Gomez de la Torre Pretell; Jeffrey Dinh; Julio Granados; Pedro O Flores-Villanueva
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

8.  Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model.

Authors:  S M Irwin; A Goodyear; A Keyser; R Christensen; J M Troudt; J L Taylor; A Bohsali; V Briken; A A Izzo
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

9.  Mycobacterium bovis BCG vaccine strains lack narK2 and narX induction and exhibit altered phenotypes during dormancy.

Authors:  Ryan W Honaker; Amanda Stewart; Stephanie Schittone; Angelo Izzo; Michèl R Klein; Martin I Voskuil
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

10.  Protection by novel vaccine candidates, Mycobacterium tuberculosis ΔmosR and ΔechA7, against challenge with a Mycobacterium tuberculosis Beijing strain.

Authors:  Sarah A Marcus; Howard Steinberg; Adel M Talaat
Journal:  Vaccine       Date:  2015-09-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.